Educational guide
Peptides for Weight Loss: What Actually Works in 2026
Peptides Calculator Guides Stacks News Compare Glossary Peptides for Weight Loss. What Fits Which Goal in 2026 Medically reviewed by the Rite Aid Health Team · Last updated August 14, 2026 Evidence and status Approval status Depends on the medication Strongest
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Approval status Depends on the medication
Strongest support Ranges from approved labeling to preclinical research
Route context Depends on the medication and indication
Competitive sport Check the specific medication
Lab work
Animal studies
Human studies
Approved label
Weight-loss goals can call for different tools. Approved medicines such as semaglutide and tirzepatide focus on appetite and long-term weight management. Tesamorelin targets visceral fat in one specific population, while MOTS-c is being studied for metabolism.
- Tesamorelin has an approved role in reducing excess abdominal fat in adults with HIV and lipodystrophy.
- MOTS-c research examines glucose handling, insulin sensitivity, weight, and waist measurements.
- Approved products containing semaglutide or tirzepatide have large controlled weight management trials.
Use this peptide therapy guide to understand the wider category.
Get the Free Peptide Tracking Toolkit
Start with Weight Loss, then review other peptide categories. Keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
Four kinds of weight-loss options
The most useful first question is where an option sits today. Approved medicines, drugs in clinical trials, indication-specific treatments, and experimental wellness compounds each come with different evidence and access.
FDA-approved weight-management medicines
| Medicine | Approved use and route | Evidence and practical question |
|---|---|---|
| Liraglutide (Saxenda) | Long-term weight reduction in labeled adults and adolescents; daily injection | Approved labeling and controlled human trials. The daily route, contraindications, and long-term plan affect whether treatment is appropriate. |
| Semaglutide (Wegovy) | Long-term weight reduction in labeled populations; weekly injection | Approved labeling and large controlled human trials. Other semaglutide products do not automatically share Wegovy's indication. |
| Tirzepatide (Zepbound) | Long-term weight reduction in labeled adults; weekly injection | Approved labeling and large controlled human trials. Eligibility, adverse effects, cost, and continued treatment all matter. |
Read the current Saxenda label, Wegovy label, and Zepbound label.
Pipeline drugs
An indication-specific treatment
| Medicine | What is approved | Why it sits apart |
|---|---|---|
| Tesamorelin | Reducing excess abdominal fat in adults with HIV and lipodystrophy; formulation-specific daily injection | Approved labeling and controlled trials support that narrow use. The label says it is not for weight management and is weight neutral. |
Experimental wellness compounds
| Compound | Best available support | What it does not establish |
|---|---|---|
| MOTS-c | Cell and animal findings; a recruiting human trial without posted results | Human weight-loss benefit, safety, route, or dose |
| AOD-9604 | FDA review of limited human studies; the larger study did not consistently show weight loss | A proven fat-loss effect or an evidence-based regimen |
| 5-amino-1MQ | Short mouse research; it is a small molecule, not a peptide | Human effectiveness, safety, or dosing |
How the main options work
- GLP-1 medicines slow digestion, reduce appetite, and improve glucose regulation. Tirzepatide adds activity at the GIP receptor.
- Tesamorelin raises growth hormone and IGF-1 through the pituitary. Its trials measured visceral abdominal fat rather than appetite-driven weight loss.
- MOTS-c is studied as a mitochondrial signal involved in cellular energy use, insulin sensitivity, and adaptation to metabolic stress.
People sometimes combine compounds because they target different goals, such as appetite and body composition. The safety and monitoring questions then come from every component in the combination.
Safety changes the decision
Approved GLP-1 and GIP-based weight medicines commonly cause digestive side effects. Their labels also cover serious risks, contraindications, interactions, pregnancy, and dose escalation.
Tesamorelin has different risks, including higher blood sugar and IGF-1. MOTS-c lacks enough human evidence to define a risk profile.
A medicine that fits one person's history may not fit another's. Review relevant conditions, medicines, pregnancy plans, and treatment goals with a licensed clinician.
A useful next step
For appetite and long-term weight management concerns, start with the GLP-1 weight loss readiness quiz.
If the concern is a change in abdominal fat linked with HIV treatment, ask specifically about the Egrifta SV indication.
Get the Free Peptide Tracking Toolkit
Start with Weight Loss, then review other peptide categories. Keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
Blood work before and during weight loss
People commonly establish a baseline before starting and repeat relevant tests during treatment. The medicine, health history, and product label determine which markers and timing matter most.
- Metabolic Profile includes glucose, liver enzymes, kidney measures, and electrolytes. It does not determine which medicine is right.
- Men's Hormone Health Checkup and Women's Hormone Health Checkup answer broader hormone questions. They are not required for every weight management medicine.
The repeat test creates a comparison with the starting point. Weight, waist measurements, side effects, appetite, and other treatment goals add information that a blood panel cannot show.
Peptide Baseline Measurement Panel
Get your baseline
- No doctor visit required
- 2,200+ Quest locations
- Results in 1–2 business days
Get your baseline
Get the Free Peptide Tracking Toolkit
Start with Weight Loss, then review other peptide categories. Keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
References
- Current Saxenda prescribing information
- Current Wegovy prescribing information
- Current Zepbound prescribing information
- FDA concerns with unapproved GLP-1 drugs used for weight loss
- Jastreboff et al.: phase 2 retatrutide trial
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Semaglutide and tirzepatide products have FDA-approved weight management indications for eligible people. Product, eligibility, dose, and safety requirements differ, so the exact label matters.
No. Egrifta SV is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Its label states that it is not indicated for weight loss.
That has not been established in humans. MOTS-c weight and metabolism findings come mainly from cell and animal studies, and there is no FDA-approved MOTS-c product.
Yes. They are peptide-based medicines that act on appetite and glucose pathways. Tirzepatide acts on both GIP and GLP-1 receptors.
Key considerations include the treatment goal, approved indication, medical history, route, side effects, cost, and expected treatment duration. A licensed clinician can assess eligibility.